Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of relapsed or refractory multiple myeloma (MM) or other plasma cell disorder (PCD)~  * At least one previous treatment for MM or PCD required~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2 OR~* Karnofsky 60-100%~Life expectancy~* At least 3 months~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Calcium ≤ 10.5 mg/dL~* No renal stone formation within the past 5 years for patients who have had curative therapy for a condition associated with the risk of stones (e.g., hyperparathyroidism, bladder dysfunction, obstructive uropathy) OR had a single episode of confirmed urolithiasis~* No calculi in urinary tract confirmed by renal ultrasonography, kidney, ureter, and bladder (KUB) x-ray, or other imaging modality~Cardiovascular~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No uncontrolled cardiac arrhythmia~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during study and for 3 months after study completion~* No osteonecrosis of the jaw~* No history of allergic reaction attributed to compounds of similar chemical or biological composition of calcitriol, paricalcitol, or zoledronate~* No uncontrolled intercurrent illness that would preclude study compliance~* No ongoing or active infection~* No psychiatric illness or social situation that may preclude study compliance~PRIOR CONCURRENT THERAPY:~Chemotherapy~* More than 4 weeks since prior chemotherapy~Endocrine~* More than 4 weeks since prior high-dose steroids~Other~* No other concurrent investigational agents or therapies for multiple myeloma or plasma cell disorders~* No concurrent digoxin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).